Your browser is no longer supported. Please, upgrade your browser.
Anavex Life Sciences Corp.
Index- P/E- EPS (ttm)-0.45 Insider Own3.63% Shs Outstand66.96M Perf Week2.13%
Market Cap391.63M Forward P/E- EPS next Y-0.52 Insider Trans0.00% Shs Float64.62M Perf Month-4.96%
Income-26.30M PEG- EPS next Q-0.11 Inst Own19.20% Short Float8.70% Perf Quarter10.79%
Sales- P/S- EPS this Y16.00% Inst Trans0.14% Short Ratio4.25 Perf Half Y29.80%
Book/sh0.45 P/B12.78 EPS next Y-13.00% ROA-81.70% Target Price- Perf Year87.91%
Cash/sh- P/C- EPS next 5Y- ROE-102.40% 52W Range2.20 - 7.69 Perf YTD6.48%
Dividend- P/FCF- EPS past 5Y7.10% ROI- 52W High-25.23% Beta0.50
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low161.36% ATR0.41
Employees20 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)53.06 Volatility7.04% 7.03%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.40% Profit Margin- Rel Volume0.41 Prev Close5.82
ShortableYes LT Debt/Eq0.00 EarningsDec 28 AMC Payout- Avg Volume1.32M Price5.75
Recom1.70 SMA201.24% SMA506.15% SMA20026.36% Volume542,926 Change-1.20%
Dec-16-20Reiterated H.C. Wainwright Buy $14 → $17
Sep-28-20Initiated Ladenburg Thalmann Buy $12
Feb-27-20Initiated Cantor Fitzgerald Overweight
Jun-18-19Initiated Janney Buy
May-16-18Resumed Maxim Group Buy $5 → $7
Mar-08-18Initiated ROTH Capital Buy $6
Feb-13-18Reiterated Maxim Group Buy $14 → $5
Sep-29-17Resumed Noble Financial Buy $15
Feb-07-17Initiated Noble Financial Buy $16
Mar-29-16Initiated FBR Capital Outperform $10
Jan-11-21 07:00AM  
Jan-06-21 07:00AM  
Jan-04-21 09:30AM  
Dec-31-20 12:00PM  
Dec-28-20 02:30PM  
Dec-22-20 07:00AM  
Dec-21-20 07:00AM  
Dec-15-20 05:57PM  
Nov-30-20 07:00AM  
Nov-27-20 10:00AM  
Nov-25-20 07:00AM  
Nov-06-20 10:45AM  
Oct-16-20 08:54AM  
Oct-15-20 03:13PM  
Sep-10-20 07:00AM  
Sep-08-20 07:00AM  
Sep-02-20 07:01AM  
Aug-19-20 07:00AM  
Aug-06-20 07:00AM  
Aug-05-20 04:05PM  
Aug-04-20 07:00AM  
Jul-06-20 07:00AM  
Jul-01-20 07:00AM  
Jun-26-20 12:00PM  
Jun-18-20 11:30AM  
Jun-16-20 07:00AM  
Jun-15-20 12:00PM  
Jun-14-20 09:07PM  
Jun-12-20 09:45AM  
Jun-11-20 06:15PM  
Jun-04-20 07:00AM  
Jun-02-20 11:30AM  
Jun-01-20 07:59AM  
May-21-20 07:00AM  
May-14-20 10:07AM  
May-13-20 12:00PM  
May-07-20 07:00AM  
May-05-20 07:00AM  
Apr-23-20 07:00AM  
Apr-14-20 11:48AM  
Apr-03-20 05:45PM  
Mar-31-20 07:00AM  
Mar-23-20 08:00AM  
Feb-24-20 07:00AM  
Feb-17-20 12:00PM  
Feb-14-20 09:18AM  
Feb-13-20 12:48PM  
Feb-11-20 09:22AM  
Feb-10-20 10:56PM  
Feb-06-20 02:30PM  
Feb-04-20 07:00AM  
Feb-03-20 07:00AM  
Jan-31-20 11:30AM  
Jan-30-20 07:00AM  
Jan-27-20 07:00AM  
Jan-23-20 08:42AM  
Jan-17-20 08:16AM  
Jan-15-20 04:34PM  
Jan-14-20 12:00PM  
Jan-08-20 08:53AM  
Dec-27-19 06:34AM  
Dec-23-19 07:57PM  
Dec-18-19 01:37AM  
Dec-16-19 07:00AM  
Dec-10-19 07:00AM  
Dec-04-19 10:13AM  
Nov-14-19 07:00AM  
Nov-06-19 07:00AM  
Oct-23-19 09:00AM  
Oct-11-19 02:04AM  
Oct-09-19 07:00AM  
Oct-02-19 07:00AM  
Sep-27-19 07:56AM  
Sep-26-19 07:00AM  
Sep-25-19 05:32PM  
Sep-19-19 08:58AM  
Sep-18-19 07:00AM  
Sep-16-19 09:00AM  
Sep-05-19 07:00AM  
Sep-04-19 07:00AM  
Aug-07-19 07:00AM  
Aug-06-19 09:54AM  
Aug-05-19 11:21AM  
Aug-02-19 11:46AM  
Aug-01-19 11:55AM  
Jul-31-19 11:14AM  
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.